Public Employees Retirement System of Ohio Makes New $7.26 Million Investment in Moderna, Inc. $MRNA

Public Employees Retirement System of Ohio bought a new stake in Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 103,730 shares of the company’s stock, valued at approximately $7,264,000.

Other hedge funds have also modified their holdings of the company. Proficio Capital Partners LLC acquired a new stake in shares of Moderna during the 2nd quarter worth about $298,000. Corient Private Wealth LP purchased a new stake in Moderna in the 2nd quarter valued at about $4,593,000. Parallax Volatility Advisers L.P. acquired a new position in Moderna in the second quarter valued at about $2,763,000. Ausdal Financial Partners Inc. acquired a new position in Moderna in the second quarter valued at about $903,000. Finally, Bamco Inc. NY purchased a new position in Moderna during the second quarter worth about $139,317,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 10.80% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Positive late-stage results from Moderna and Merck’s personalized melanoma vaccine remain the primary catalyst. The data reinforced expectations that Moderna can expand beyond COVID-19 vaccines into cancer immunotherapy and potentially create a significant long-term revenue stream. Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?
• Positive Sentiment: Options activity was notably bullish, with investors purchasing 106,605 call contracts—about 35% above typical volume. The activity suggests increased speculative interest in further gains, although options positioning can also amplify volatility.
• Positive Sentiment: Moderna’s updated COVID-19 vaccine approvals and the company’s recent momentum have helped restore investor confidence in its commercial and regulatory execution. Shares more than doubled during August, making the stock one of the market’s strongest performers. Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally
• Neutral Sentiment: Moderna will present at the Morgan Stanley Global Healthcare Conference on September 14 and the Bernstein Healthcare Forum on September 23. These events could provide updates on the oncology pipeline, vaccine demand and the path to profitability, but no new financial information was announced. Moderna to Present at Upcoming Conferences in September 2026
• Negative Sentiment: GSK advanced its competing mRNA influenza vaccine into a Phase III trial, increasing future competitive pressure shortly after Moderna received approval for the first seasonal flu mRNA vaccine. Investors appear to be treating the threat as manageable for now, with greater emphasis on Moderna’s cancer program. GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial
• Negative Sentiment: Brookline Capital Markets modestly reduced its FY2029 and FY2030 EPS estimates, while maintaining a Buy rating. The cuts signal limited near-term financial visibility as Moderna remains loss-making and analysts expect a full-year loss.

Moderna Price Performance

Shares of MRNA opened at $154.27 on Wednesday. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $176.66. The firm’s 50 day moving average price is $80.59 and its 200 day moving average price is $61.34. The company has a market cap of $61.59 billion, a P/E ratio of -19.31 and a beta of 1.09. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned ($2.13) EPS. On average, research analysts forecast that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. CLSA raised shares of Moderna to an “outperform” rating in a research note on Friday. Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research report on Wednesday, August 19th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $130.00 target price on shares of Moderna in a research report on Wednesday, August 19th. Bradesco Corretora upgraded Moderna to an “outperform” rating in a research note on Friday. Finally, Morgan Stanley raised their price target on Moderna from $39.00 to $89.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 20th. Seven analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $80.53.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.